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Abstract
Aims/hypothesis The effect of n-3 fatty acid treatment on vi-
bration perception thresholds (VPTs) and cutaneousmicrovas-
cular reactivity is not known. We tested whether: (1) a 15–
18month treatment with high dose (4 g/day) docosahexaenoic
(DHA) plus eicosapentaenoic (EPA) acid improved VPT and
microvascular reactivity in patients with non-alcoholic fatty
liver disease; and (2) there are associations between VPT,
microvascular reactivity and metabolic variables.
Methods In the completed single centre, randomised, parallel
group, placebo controlled Wessex Evaluation of fatty Liver
and Cardiovascular markers in non-alcoholic fatty liver dis-
ease with OMacor thErapy (WELCOME) trial, we tested the
effect of DHA+EPA on VPT at 125 Hz (big toe) and the
cutaneous hyperaemic response (forearm) to arterial occlusion
(ratio of maximum to resting blood flux [MF/RF]). Allocation
and dispensing was carried out by an independent research
pharmacist; all participants and research team members were
blinded to group assignment.
Results In all, 51 and 49 patients were randomised to placebo
and DHA+EPA, respectively (mean age 51.4 years). Of these,
32 had type 2 diabetes. Forty-six (placebo) and 47 (DHA+
EPA) patients completed the study; there were no important
adverse (or unexpected) effects or side effects. In
multivariable-adjusted regression models (intention-to-treat
analyses), DHA+EPA treatment was associated with an in-
crease in VPT (β coefficient 1.49 [95% CI 0.04, 2.94], p=
0.04). For VPT, the adjusted mean differences (95% CIs) in
the placebo and DHA+EPA treatment groups were −0.725
(−1.71, 0.25) and 0.767 (−0.21, 1.75) m/s2, respectively.
With DHA+EPA treatment, there was no change in MF/RF
(β coefficient 0.07 [95% CI −0.56, 0.70], p=0.84), the adjust-
ed mean differences (95% CIs) in the placebo and DHA+EPA
treatment groups were −0.549 (−1.03, −0.07) and −0.295
(−0.77, 0.18) respectively. VPTwas independently associated
with age (β coefficient 0.019 [95% CI 0.010, 0.029],
p<0.0001) and MF/RF (β coefficient −0.074 [95% CI
−0.132, −0.016], p=0.013), but not with diabetes ( p=0.38).
Conclusions/interpretation High dose n-3 fatty acid treatment
did not improve measures of microvascular function or vibra-
tion perception. Ageing and microvascular reactivity are asso-
ciated with a measure of peripheral nerve function.
Trial registration: ClinicalTrials.gov NCT00760513
Funding: The study was funded by the National Institute for
Health Research UK and Diabetes UK.
Keywords n-3 Fatty acid . Insulin resistance .
Microcirculation . Non-alcoholic fatty liver disease . Omacor/
Lovaza . Sensory nerves . Type 2 diabetes . Vibration
perception threshold
Abbreviations
CIMT Carotid intima–media thickness
DXA Dual energy x-ray absorptiometry
DHA Docosahexaenoic acid
* Christopher D. Byrne
cdtb@soton.ac.uk
1 Human Development and Health Academic Unit, Faculty of
Medicine, University Hospital Southampton, MP887, IDS Building,
Tremona Road, Southampton SO166YD, UK
2 National Institute for Health Research Southampton Biomedical
Research Centre, University of Southampton and University Hospital
Southampton NHS Foundation Trust, Southampton, UK
3 Institute of Sound and Vibration Research, University of
Southampton, Southampton, UK
Diabetologia (2015) 58:1916–1925
DOI 10.1007/s00125-015-3628-2
EPA Eicosapentaenoic acid
IR Insulin resistance
MF Maximum flux
MR Microvascular reactivity
MRS Magnetic resonance spectroscopy
NAFLD Non-alcoholic fatty liver disease
NIHR National Institute for Health Research
PU Perfusion units (arbitrary)
RF Resting flux
VPT Vibration perception threshold
WELCOME Wessex Evaluation of fatty Liver and
Cardiovascular markers in NAFLD with
OMacor thErapy
Introduction
Peripheral neuropathy and impaired microvascular function
are strong risk factors for foot ulceration and impaired wound
healing in people with diabetes [1], and both somatic cutane-
ous sensory fibre neuropathy and microvascular dysfunction
are early complications of diabetes mellitus and/or insulin
resistance (IR) in obese individuals [2]. Screening tests for
neuropathy in the clinic include use of a 10 g monofilament
and of a 128 Hz tuning fork [3]. Both tests reflect the function
of large myelinated sensory nerve fibres; however, although
the monofilament test has been widely adopted and is easy to
use in clinical practice, its sensitivity to detect early impair-
ment in nerve function is limited [4]. In contrast, use of vibra-
tion perception thresholds (VPTs) allows not only detection of
neuropathy but also assessment of the severity of the sensory
nerve impairment [5]. The prevalence of an abnormal VPT in
patients with type 2 diabetes has been shown to be >11% [6],
and an abnormal VPT is an excellent predictor of foot ulcer-
ation, limb amputation and mortality in patients with type 2
diabetes [7].
Non-invasive assessment of cutaneous microvascular reac-
tivity (MR) has been widely used to assess microvascular
endothelial and neurovascular function in patients at an in-
creased risk of cardiometabolic disease [8] and is indicative
of MR in other vascular beds [9]. Impaired skin MR strongly
relates to impaired glucose tolerance, IR and obesity [10, 11];
whilst microvascular and neurological function are interlinked
in diabetes [12], there is still controversy about whether early
changes in microvascular function or changes in metabolic
variables have the greater influence on peripheral nerve func-
tion [13].
Treatment with high dose long chain n-3 polyunsaturated
fatty acids such as eicosapentaenoic acid (EPA, 20:5 n-3) and
docosahexaenoic acid (DHA, 22:6 n-3) improves endothelial
function [14]. These fatty acids enhance nerve blood flow [15],
may improve vibration perception and clinical symptoms of
neuropathy in patients with type 2 diabetes [16], and have been
shown to be protective against paclitaxel-induced peripheral
neuropathy [17]. However, although there is some preliminary
evidence of benefit of long chain n-3 fatty acids in patients
with neuropathy, it remains uncertain whether these fatty acids
have beneficial effects on VPTs and maximum flux (MF).
Patients with IR and non-alcoholic fatty liver disease
(NAFLD) have an increased risk of type 2 diabetes and its
complications, including macrovascular disease [18, 19].
Additionally, NAFLD is associated with impaired coronary
microvascular function [20], increased risk of retinal micro-
vascular disease and prevalence of peripheral neuropathy [21].
Since the effect of high dose n-3 fatty acid treatment on nerve
function and microvascular function in high risk patients for
type 2 diabetes and its complications is not known, we tested
whether high dose n-3 fatty acid treatment has beneficial ef-
fects on VPTs and MF in this patient group. Specifically, we
tested whether an 15–18 month treatment with high dose
DHA+EPA (4 g/day as ethyl esters) produced improvements
in VPTs andMR in patients with NAFLD, some of whom had
type 2 diabetes; however, all patients were without clinical
evidence of peripheral neuropathy or microvascular disease.
In a pre-specified substudy of the Wessex Evaluation of fatty
Liver and Cardiovascular markers in NAFLD with OMacor
thErapy (WELCOME) trial (ClinicalTrials.gov registration
no. NCT00760513) [22, 23], a randomised, double blind,
placebo controlled trial, we tested the effect of DHA+EPA
treatment on VPT and MR.
Methods
Study design A cohort of 105 individuals (60 men and 45
women; mean age 51.4 years) was studied. The participants
formed part of the WELCOME study, a randomised, double
blind, placebo controlled trial [22] (approved by the local
research ethics committee [REC: 08/H0502/165]).
Participants were block randomised by an independent clini-
cal trials pharmacist to treatment with identical capsules by
mouth of either n-3 fatty acid ethyl esters (4 g/day Omacor;
Pronova, Sandefjord, Norway) or placebo (4 g/day olive oil)
for a minimum of 15 months and a maximum of 18 months.
Only the clinical trials pharmacist was unblinded, and
randomisation group allocation was concealed from all study
members throughout the trial. One gram of Omacor contains
460 mg EPA and 380 mg DHA 380 mg as ethyl esters.
Omacor is approved by the Food and Drug Administration
and the European Medicines Agency at a dose of 2–4 g/day
for the treatment of hypertriglyceridaemia. Olive oil placebo
contained ~67% oleic acid, ~15% linoleic acid, ~15% palmitic
acid. ~2% stearic acid and ~1% α-linolenic acid. Participants
were unpaid and gave written informed consent. Inclusion
criteria were a diagnosis of NAFLD based on liver biopsy or
the presence of hepatic steatosis on ultrasound, and exclusion
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of other liver diseases. Participants were excluded from the
final analyses if they had evidence of distal peripheral neurop-
athy in their feet (n=4), as suggested by their failure to detect a
10 g monofilament [24], or if they had evidence of diabetic
eye disease at retinal screening (n=0).
All tests for peripheral neurological and microvascular
function were conducted in a temperature controlled room
(22–24°C). Skin temperature at the toe, if below 25°C,
was raised with a heat pad to 25°C prior to vibration
testing. Mean ± SD skin temperature measured at the
toe was 28.3±2.5°C (range 25.0–35.1°C) and at the fore-
arm was 29.3±0.7°C (range 27.5–31.1°C). Participants
refrained from caffeine-containing drinks, smoking and
exercise for ≥2 h prior to testing. Measurements were
made at baseline and at the end of the study.
Vibrotactile perception VPTs at 125 Hz were measured
(Vibrotactile Perception Meter; HVLab Diagnostics
Instruments, Southampton, UK) with a 6 mm diameter probe
and a 2 mm gap to a 10 mm diameter surround [25]. VPTs
were determined using the von Békésy method [25]. For this,
the vibration magnitude was alternately increased and de-
creased by 3 dB/s according to whether the participant felt
the vibration. A response button was pressed when the vibra-
tion was felt and released when the vibration was not felt.
Measurements continued for 30 s or until a minimum of six
pairs of reversals had been obtained, after excluding the first
pair. Thresholds (m/s2) were determined from the arithmetic
averages of the logarithms of the root mean square vibration
acceleration at the reversals [26]. Tests were performed on the
pulp of the left great toe at baseline and the end of the study.
The intra-individual CV was 22% as measured in 20 volun-
teers on two occasions.
Microvascular function Cutaneous MR was assessed on the
ventral surface of the non-dominant forearm arm using laser
Doppler fluximetry (Moor VMS LDF2 and DP1T probe;
Moor Instruments, Axminster, UK) [27]. Blood flux was re-
corded continuously before and during the dilator response to
transient ischaemia (180 mmHg for 3 min; MoorVMS-
PRES). The post-occlusive hyperaemic response is an inte-
grated vascular response involving neural, endothelial and
vascular smooth muscle activity, and is analogous to that used
to assess endothelial function in conduit arteries [8]. Values
for microvascular perfusion in arbitrary perfusion units (PUs)
were determined at rest (i.e. resting flux [RF]: mean value over
the final 5 min before perturbation) and at maximum value
after release of the pressure cuff (MF) using the manufacturer’s
software (MoorVMS-PC software; Moor Instruments). MR
was expressed as the ratio of maximum to resting blood flux
(MF/RF). The intra-individual CV measured in the forearm of
10 volunteers on two occasions, 7 days apart, was 15% for the
RF and 19% for the MF/RF.
Biochemical and anthropometric measurements
Measurements were made at baseline and at the end of the
intervention period. Glucose, insulin, total cholesterol, HDL-
cholesterol and triacylglycerol concentrations were measured
in fasting serum or plasma using commercially available kits
according to the manufacturers’ instructions. HbA1c was mea-
sured by high pressure liquid chromatography (Bio-Rad
Laboratories, Irvine, CA, USA). HOMA-IR was calculated
from fasting insulin and fasting glucose concentrations [28].
Blood pressure was measured in the non-dominant arm after
participants had become acclimatised and had rested for at
least 60 min; the mean of three measurements was calculated.
Dual energy x-ray absorptiometry (DXA), MRI and magnetic
resonance spectroscopy (MRS) were undertaken to assess
body fat (total body fat, regional body fat and visceral fat)
and quantify liver fat [22]. Liver fibrosis was assessed using
the NAFLD fibrosis score [29] and an additional validated
liver fibrosis score [30]. Carotid intima–media thickness
(CIMT) was measured at both carotid arteries with B-mode
ultrasound and a mean value was calculated. This measure is a
recognised marker of subclinical atherosclerosis [31] and has
prognostic value in cardiovascular disease [32]. The overall
10 year risk of cardiovascular disease was calculated using the
QRISK 2011 online calculator (www.qrisk.org).
Statistical analysis Statistical analyses were undertaken
using IBM SPSS Statistics software (version 21.0, Chicago,
IL, USA). Data are reported as the mean ± SD for normally
distributed variables, or the median and interquartile range for
non-normally distributed variables. Where possible, variables
that were not normally distributed were normalised by log
transformation for parametric statistical analyses. Pearson
and Spearman rank r coefficients were used to investigate
associations between normally and non-normally distributed
variables, respectively. In all cases, a p value of <0.05 was
taken to indicate significance.
We tested the independence of associations between base-
line factors and the two primary outcomes (VPT and MF/RF)
at baseline by multivariable linear regression. We tested the
effects of DHA+EPA treatment on both key outcomes of in-
terest (change in VPT at 125 Hz and change in MF/RF from
baseline to the end of the study) using multivariable linear
regression; and logistic regression for dichotomous outcomes
of VPT difference (increased/decreased) and MF/RF (in-
creased/decreased). ANCOVAwas also used to assess adjust-
ed mean differences (95% CIs) for both outcomes of interest
in the placebo and DHA+EPA groups. These analyses includ-
ed all participants with complete data (i.e. baseline and end of
study measurements). For all regression models and for
ANCOVA, there was also adjustment for baseline measure-
ment of the outcome variable in question, and adjustment also
for key covariates and confounders. We also explored the
effect of medication usage (statins, metformin, antidepressants
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and antihypertensive drugs, including calcium antagonists; no
patients were taking hydralazine).
Results
Characteristics of the trial participants Figure 1 shows the
CONSORT diagram for recruitment into the study and the
reasons for withdrawal. Table 1 shows the baseline character-
istics of participants without overt neuropathy or microvascu-
lar disease, stratified by diabetes status and by randomisation
status. The mean ± SD age was 51.7±10.9 years for the 69
individuals (38 men) without diabetes and 50.1±10.3 years
for the 32 individuals (20 men) with type 2 diabetes. Thirteen
participants were current smokers and three had suffered from
ischaemic heart disease. Of the participants, 41 were taking
statins, 36 were taking antihypertensive drugs (nine calcium
antagonists) and 27 were taking metformin. The VPT at
125 Hz and MF/RF did not differ between individuals with
and without diabetes (Table 1). Of the participants without
diabetes, ~50% had impaired fasting glucose or impaired glu-
cose tolerance.
Associations of VPT at 125 Hz and MF/RF with cardio-
vascular and metabolic risk factors at baseline In univari-
ate analyses, VPT was associated with age (r=0.507, p=
0.0001) and MF/RF (r=−0.301, p=0.002; Table 2). The scat-
ter plot for the association between VPTand MF/RF is shown
in Fig. 2. The VPT was positively associated with CIMT (r=
0.358, p=0.0001). An increase in VPT and a decline in MF/
RFwere both associated with an increase in QRISK (r=0.416,
p=0.0001 and r=−0.229, p=0.023, respectively).
There was no significant association between either VPTat
125 Hz or MF/RF and measures of obesity, glycaemic status
or IR; however, in individuals without diabetes, MF/RF was
negatively correlated with HOMA-IR (r=−0.326, p=0.006,
n=69). Stratification by diabetes status suggested that in indi-
viduals with diabetes, an increase in VPTwas associated with
an increase in duration of diabetes (r=0.485, p=0.005).
A multivariable regression model with baseline VPT as the
outcome variable, and age, sex, MF/RF, diabetes status, liver
fibrosis score and CIMTas exposure variables, showed that all
of these together explained ~35% of the variance in VPT (R2=
0.35, p<0.001, adjusted R2=0.30; Table 3). The use of statins,
metformin, antidepressants or all antihypertensive drugs (in-
cluding calcium antagonists) was not independently associa-
ted with VPT at 125 Hz. The model was also unaffected by
adjustment for skin temperature (data not shown). We repea-
ted the model replacing diabetes status with IR (HOMA-IR).
In this model, age, sex, MF/RF, HOMA-IR, liver fibrosis
score and CIMT explained ~33% of the variance in sensory
nerve function (R2=0.325, p=0.0001, adjusted R2=0.276) in
the whole cohort.
We repeated the regressionmodel, with VPT replacingMF/
RF as the new outcome (in Table 3). In a model that included
VPT, age, diabetes status, liver fibrosis score, use of calcium
antagonists and CIMT as exposure variables, female sex ( p=
0.010), VPT ( p=0.011) and use of calcium antagonists
( p<0.0001) were significant (R2=0.27, adjusted R2=0.21,
p<0.001). Use of other antihypertensive agents was not asso-
ciated with MF/RF. Replacing diabetes status with HOMA-IR
Participants with neuropathy (n=4)
Participants completed baseline visit (n=105)
Start and end measurements available 
For VPT (n=90) and MF/RF (n=92) 
Baseline data without neuropathy (n=101)
Participants allocated to Omacor (n=49) Participants allocated to placebo (n=51)
Participants allocated to Omacor 
(VPT n=44, MF/RF n=45, Diabetes n=14)
Participants allocated to placebo 
(VPT n=46, MF/RF n=47, Diabetes n=16)
Participant not randomised (n=1)
Fig. 1 CONSORT diagram. Five
participants were excluded (four
for neuropathy, and one was not
randomised because of illness)
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as an exposure variable did not improve the model (R2=0.23,
adjusted R2=0.17, p=0.003), and HOMA-IR was not inde-
pendently associated with MF/RF ( p=0.97).
Effect of n-3 polyunsaturated fatty acid treatment on VPT
at 125 Hz andMF/RF Table 1 shows the baseline character-
istics of those participants without overt neuropathy or micro-
vascular disease, by randomisation status. By chance, VPT
was higher in participants randomised to placebo compared
with DHA+EPA at baseline; to take account of this difference,
the regression models were adjusted for baseline measure-
ment. Table 4 shows the results of multivariable regression
modelling to test the effects of the DHA+EPA intervention
on both outcomes (i.e. change in VPT or change in MF/RF).
In regression modelling with adjusting for key potential con-
founders (age, sex, VPTat baseline,MF/RF, diabetes [yes/no],
a liver fibrosis marker and mean CIMT), there was a small
increase (i.e. worsening) in the VPT difference with DHA+
EPA treatment. The model explained ~33% of the variance in
VPT difference (R2=0.33, p<0.0001, adjusted R2=0.27). The
model was slightly improved when diabetes (yes/no) was re-
placed with HOMA-IR as a measure of IR (R2=0.37,
p<0.0001, adjusted R2=0.29). None of the medications tested
affected the model or were associated with either outcome.
Since there was a significant (and unexpected) effect of
DHA+EPA in increasing VPT at the end of the study, we
Table 1 Baseline characteristics according to diabetes status and according to randomisation group
Variable Diabetes Randomisation
No (n=69) Yes (n=32) p value Placebo (n=51) DHA+EPA (n=49) p value
Sex, M/F 38/31 20/12 34/17 24/25
Age, years 51.7±10.9 50.1±10.3 0.66 53.8±9.7 48.2±11.1 0.27
BMI, kg/m2 31.3 (5.0) 35.2 (7.5) 0.004 31.7 (5.2) 32.8 (7.1) 0.42
Duration of diabetes, years 5 (7) 6 (5) 3 (5) 0.45
Diabetes 17 15 –
Current smoker 10 3 0.54 6 7 0.71
10 year cardiovascular disease riska, % 8.5 (12.9) 15.0 (14.9) 0.014 10.9 (13.6) 8.5 (13.4) 0.26
Systolic BP, mmHg 137 (22) 138 (20) 0.77 137 (17) 135 (26) 1.0
CIMT, mm 0.65 (0.12) 0.65 (0.13) 0.87 0.66 (0.9) 0.62 (0.13) 0.23
Cholesterol, mmol/l 4.6 (1.4) 4.3 (2.3) 0.0009 4.6 (1.4) 4.9 (1.3) 0.07
LDL-cholesterol, mmol/l 2.9 (1.2) 2.6 (1.0) 0.013 2.8 (1.0) 3.0 (1.3) 0.19
HDL-cholesterol, mmol/l 1.1 (0.4) 1.0 (0.3) 0.11 1.0 (0.3) 1.0 (0.4) 0.42
Cholesterol/HDL 5.1±1.5 4.7±1.5 0.23 4.6±1.4 5.2±1.6 0.11
Triacylglycerol, mmol/l 1.8 (1.3) 1.5 (1.0) 0.62 1.5 (1.0) 1.8 (1.2) 0.55
Total body fatb, % 38.1±7.5 37.9±7.0 0.48 35.7±6.9 39.9±7.1 0.38
Subcutaneous fatc, % 32.8±9.6 31.6±10.1 0.56 29.9±9.4 34.9±10.2 0.14
Visceral fatc, % 16.2±4.6 16.7±5.1 0.64 17.0±4.6 15.5±5.0 0.30
Liver fatd, % 26 (26.3) 23.3 (21.5) 0.54 24.0 (20.1) 23.5 (33.9) 0.92
Liver fibrosis score [29] 8.78±0.74 9.25±0.99 0.01 9.05±0.80 8.85±0.89 0.15
NAFLD fibrosis score [28] –1.99±1.24 –0.73±1.42 0.0001 –1.67±1.35 –1.52±1.50 0.61
IRe 2.6 (2.4) 4.6 (5.0) 0.002 2.8 (3.2) 3.2 (3.2) 0.60
HbA1c, % 5.8 (0.6) 7.6 (2.6) <0.0001 6.1 (1.6) 5.9 (1.2) 0.13
HbA1c, mmol/mol 40 (6.6) 60 (28.4) 43.2 (17.5) 41.8 (13.1)
VPT at 125 Hz, m/s2 3.8 (5.5) 4.2 (7.5) 0.48 5.8 (6.5) 3.4 (4.0) 0.026
RF, PU 10.7 (6.8) 12.1 (6.8) 0.0630 12.4 (7.8) 10.4 (8.1) 0.110
MR (MF/RF) 4.2 (1.9) 4.7 (2.5) 0.3218 4.3 (2.0) 4.2 (2.4) 1.0
Data are the mean ± SD or median (interquartile range)
a QRISK2
bDXA
cMRI
dMRS
eHOMA-IR
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assessed adjustedmean differences in placebo and DHA+EPA
treatment groups. The adjusted mean differences (95% CIs) in
the placebo and DHA+EPA treatment groups were −0.725
(−1.71, 0.25) and 0.767 (−0.21, 1.75), respectively. These data
are in keeping with the unstandardised β coefficient from the
regression modelling analyses, showing the treatment effect
(i.e. 1.492; Table 4). We also assessed the OR (95% CI) for a
worsening of VPT difference with DHA+EPA treatment.
These data (OR 2.47 [95%CI 0.97, 6.32], p=0.058) were also
consistent with the results frommultivariable linear regression
modelling and ANCOVA. Next, we tested whether there was
an interaction between DHA+EPA treatment and the baseline
VPT measurement. These analyses showed a significant asso-
ciation between the interaction term and change in VPT
(Table 4).
We repeated the regression model with VPT difference
replacing MF/RF difference as the outcome (Table 4).
Variables included in the model explained 35% of the variance
in MF/RF difference (R2=0.35, p<0.0001, adjusted R2=
0.28), but there was no effect of the DHA+EPA intervention
( p=0.84; Table 4). The adjusted mean differences (95% CIs)
in the placebo and DHA+EPA treatment groups were −0.549
(−1.03, −0.07) and −0.295 (−0.77, 0.18) respectively. Figure 3
shows individual baseline and end of study measurements for
VPT and MF/RF for each participant. Stratifying by diabetes
status showed there was no specific benefit of DHA+EPA
treatment on VPT ( p=0.36) or MF/RF ( p=0.53) in people
with diabetes.
Discussion
Our study is the first randomised, double blind, placebo con-
trolled trial to examine the effects of the highest licensed dose
of n-3 fatty acids on measures of vibration perception and
microvascular function. Our novel data show that there was
no benefit of high dose DHA+EPA treatment for 15–
18 months on VPT or MR. In fact, our results show that with
DHA+EPA treatment there was a small, albeit significant,
increase in VPT between baseline and the end of the study
(Table 4) that is unlikely to be of clinical relevance. Although
we show an independent association between VPT and MF/
Table 2 Univariate associations between the VPTor MR (MF/RF) and
anthropometric and biochemical risk factors at baseline
Variable VPT at 125 Hz MRa
r value p value r value p value
Age (years) 0.507 0.0001 −0.179 0.073
BMI (kg/m2)b −0.156 0.123 0.074 0.465
Duration of diabetesb, years (n=32) 0.567 0.001 −0.281 0.119
CVD riskb, % 0.416 0.0001 −0.229 0.023
Systolic BP, mmHg 0.046 0.654 −0.163 0.164
CIMT (mm) 0.358 0.0001 −0.092 0.368
Cholesterol/HDL −0.122 0.229 −0.041 0.686
Total body fatb, % −0.029 0.776 0.029 0.777
Subcutaneous fatb,c, % −0.106 0.315 0.088 0.402
Visceral fatc, % 0.114 0.281 −0.132 0.209
Liver fatb,d, % 0.088 0.395 −0.044 0.667
Liver fibrosis score [29] 0.146 0.155 0.065 0.526
NAFLD fibrosis scoreb [28] 0.200 0.047 −0.087 0.387
IRe 0.070 0.507 −0.103 0.324
HbA1c
b, % 0.073 0.474 0.110 0.275
VPT at 125 Hz, m/s2 – – −0.301 0.002
MR (MF/RF) −0.301 0.002 – –
Data are Pearson or Spearman r coefficients
n=101
aMF/RF
b Spearman r coefficients
cMRI
dMRS
eHOMA-IR
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Fig. 2 Scatter plot showing the relationship between baseline VPT (log10
VPT) at 125 Hz and cutaneous MR (log10 MF/RF)
Table 3 Multivariable regression model with the VPT as the outcome
and key covariates and potential confounders as explanatory variables
Variable Unstandardised
β coefficient
95% CI p value
Age, years 0.019 0.010, 0.029 0.0001
Male sex 0.031 −0.142, 0.203 0.72
MR (MF/RF) −0.074 −0.132, −0.016 0.013
Diabetes status 0.080 −0.102, 0.262 0.38
Liver fibrosis score,
AU [29]
0.017 −0.089, 0.123 0.75
CIMT (mm) 0.544 −0.469, 1.557 0.29
Antihypertensive drug
(calcium antagonistsa)
−0.268 −0.593, 0.057 0.11
For the model, R2 =0.35 ( p<0.001), adjusted R2 =0.30 ( p<0.001)
a Other antihypertensives were not associated with VPT
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RF at baseline (Table 3), this association was weaker at the
end of the study (data not shown).We consider that the change
in association between these two variables (between baseline
and end of study) may have been caused by two factors (illus-
trated in Table 4): (1) the significant interaction between
DHA+EPA treatment and baseline VPT, and the association
of both factors with the change in VPT during the study; and
(2) the DHA+EPA treatment-mediated increase in the end of
study VPT.
Whilst there is general agreement that microvascular and
neurological function are interlinked in diabetes, there is still
controversy over the pathogenesis of neuropathy and uncer-
tainty as to whether metabolic or vascular risk factors (includ-
ing impaired MR) are more important in influencing VPTs in
people at risk of diabetic foot ulceration [13]. In addressing
this uncertainty, our results suggest that ageing and early
changes in microvascular function have a greater influence
on peripheral nerve function than metabolic variables.
We do not have measurements of DHA or EPA tissue en-
richment in nerves or the microvasculature. However, we have
shown that the DHA+EPA treatment caused excellent enrich-
ment in erythrocytes and there was good adherence to the
Table 4 Multivariable linear regressionmodelling testing the effects of treatment on each of the primary outcomes, adjusting for baseline measurement
of each outcome, and key covariates and potential confounders
Independent variable Primary outcome
Change in VPTa, m/s2 Change in MRa, MF/RF
Unstandardised
β coefficient
95% CI p value Unstandardised
β coefficient
95% CI p value
DHA+EPA treatment 1.492 0.04, 2.94 0.04 0.07 −0.56, 0.70 0.84
Age, years 0.04 −0.04, 0.13 0.32 −0.03 −0.06, 0.01 0.16
Male sex −1.07 −2.53, 0.39 0.15 0.60 −0.06, 1.25 0.08
Diabetes status 1.36 −0.11, 2.83 0.07 −0.14 −0.81, 0.53 0.68
VPT, m/s2 −0.30 −0.44, −0.17 <0.0001 0.02 −0.11, 0.15 0.77
MF/RF −0.17 −0.63, 0.29 0.47 −0.63 −0.84, 0.42 <0.0001
Liver fibrosis score [29] −0.23 −1.16, 0.70 0.63 0.03 −0.38, 0.44 0.89
Mean CIMT, mm −4.16 −12.40, 4.07 0.32 0.02 −3.72, 3.75 0.99
Treatment × baseline VPT, m/s2 0.31 0.06, 0.56 0.015 – – –
Treatment × baseline MR (MF/RF) – – – 0.16 −0.24, 0.57 0.42
Placebo group, n=46; treatment group, n=47
Each regression model was adjusted for age, sex, outcome variable value at baseline (i.e. VPT or MF/RF), plus diabetes status (yes/no), a marker of
NAFLD severity (liver fibrosis score) and a marker of preclinical macrovascular disease status (mean CIMT of left and right common carotid arteries)
a From baseline to the end of the study
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Fig. 3 Effect of 15–18 month
treatment with DHA+EPA ethyl
esters (4 g/day) or placebo on
cutaneous microvascular dilator
capacity and VPT at 125 Hz. (a)
and (c) show the placebo group
and (b) and (d) show the
treatment group. Baseline and end
of study (End) median
measurements for each group are
indicated by a horizontal line
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intervention (all participants consumed ~75% of their allocat-
ed capsules) [23]. Whilst we did not undertake prior sample
size calculations for this pre-specified substudy, our results
provided no hint of improvement with the intervention
(Table 4). A retrospective power calculation showed that with
the number of patients completing the trial and α=0.05, we
had 99% power to detect a 20% change in MF/RF. Although,
it has been previously suggested that a 6 week treatment with
DHA had beneficial effects on forearm blood flow in obese
individuals [14] and that n-3 fatty acid treatment (in a non-
randomised study) improved vibration perception in 21 pa-
tients with type 2 diabetes [16], prior to our study these ben-
efits of DHA+EPA had not been tested in randomised, double
blind, placebo controlled trials lasting over 12 months.
Importantly, the association between VPT and MF/RF at
baseline remained significant after adjusting for potential con-
founders such as age, sex, diabetes status, obesity, NAFLD
severity or CIMT. In our study, stratifying by diabetes status
showed that there was no association between VPT and IR
(HOMA-IR) in people with diabetes. There was also no asso-
ciation between VPT and current glycaemic control (HbA1c),
but there was a significant association between VPT and
HOMA-IR in people who did not have diabetes (r=0.342,
p=0.005; n=67). This latter finding most likely reflects the
fact that HOMA-IR measurements are an inaccurate estimate
of IR in people with diabetes who have pancreatic beta cell
failure. Our findings are also consistent with the results of a
study of 156 individuals with peripheral neuropathy and dia-
betes, which showed no association between neuropathy and
glycaemic control [12]. These findings and our data, taken
together, suggest strongly that peripheral neurological func-
tion is more closely associated with a measure of microvascu-
lar health than with metabolic risk factors, with the exception
of IR. Microvascular dysfunction has been proposed to be a
link between obesity, IR and hypertension [33], and a reduced
microvascular dilator and exchange capacity has consistently
been reported by us and by others in individuals with features
of the metabolic syndrome [34–37]. With respect to a link
between VPT and HOMA-IR, it is important to note that the
DHA+EPA intervention did not improve HOMA-IR (data not
shown but available from the authors).
Peripheral neuropathy is associated with cardiovascular
disease [38], and increased vibration thresholds have been
shown to be a risk factor for mortality with diabetes [39].
We showed for the first time a strong association between
VPTat 125 Hz and CIMT (Table 2). CIMT is a reliable marker
of preclinical atherosclerosis, and NAFLD is an independent
predictor of an increased CIMT [40]. Endothelial dysfunction
may occur early in NAFLD [41] and it has been suggested that
the mechanisms associated with arterial thickening could im-
pair blood flow and initiate endoneurial hypoxia, which is
thought to play a significant role in causing peripheral neurop-
athy in diabetes [42].
We are not able to explain what aspect of ageing underpins
the association between age and VPT. Sensory perception
decreases with age, and higher mechanical and thermal sen-
sory perception thresholds have been observed in older people
[43]; however, whether any decrease in perception occurs as a
result of changes in the brain, spinal cord, or peripheral nerves
or receptors is uncertain. Our finding that higher VPTs were
associated with an increased duration of diabetes is consistent
with results reported by Shun et al [44] in people with type 2
diabetes. These authors additionally reported that diabetes du-
ration was negatively associated with epidermal denervation,
an early event in people with diabetes [45]. It is plausible that
IR and advanced protein glycation [46] combine with delete-
rious changes in nerve perfusion through components of in-
flammation and oxidative stress [47] and may be responsible
for the increase in VPT, but this is speculation and further
research is needed.
Limitations The current study has strengths and limita-
tions. The main strength is that we have undertaken a
randomised, double blind, placebo controlled trial testing
the effects of highly purified long chain n-3 fatty acids
lasting 15–18 months. We cannot overlook the fact that
perfusion of skin capillaries primarily serves the purpose
of thermoregulation, whereas those in deeper tissues (e.g.
skeletal muscle) are much more closely linked to metabol-
ic demand; nevertheless, the ability to perform minimally
invasive in vivo mechanistic studies in human skin can
inform our understanding of how disease states adversely
affect vascular function. There is no ideal biomarker for
diagnosis of neuropathy in diabetes. We have used
neurothesiometry (VPT) to derive a quantitative measure-
ment of peripheral nerve function and VPT at 125 Hz that
is neuroselective for large myelinated sensory nerve fi-
bres. Recently, it has been shown that nerve dysfunction
in large nerve fibres occurs in individuals with impaired
glucose tolerance compared with health controls [48].
Dysfunction in small nerve fibres may precede large nerve
fibre dysfunction in diabetic neuropathy [13, 49].
However, since we measured VPT, we cannot comment
on the effect of DHA+EPA on small nerve fibre function
or on the relationship between MR, ageing and HOMA-IR
and small nerve fibre function. We also cannot be sure of
the effect of duration of diabetes on VPT in our cohort
because identification of the date of onset of type 2 dia-
betes is often imprecise. Additionally, we undertook as-
sessment of VPT in the foot and microvascular function in
the arm. It was technically challenging in this obese co-
hort to measure microvascular function in the lower leg,
and it is well accepted that the cutaneous arm microcircu-
lation provides a well-validated index of microvascular
function indicative of MR in other, less accessible vascu-
lar beds [9, 50].
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Conclusion Treatment with the highest licensed dose of
DHA+EPA (as Omacor/Lovaza) did not improve VPT or
MR in patients with NAFLD. In a high risk patient group
without evidence of overt peripheral neuropathy, both ageing
and a measure of MR were independently associated with
VPT. VPT is more strongly related to a measure of microvas-
cular health than to metabolic risk factors, with the exception
of IR.
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